Tesofensine for weight loss: what the hype gets wrong

What did @joe_vito_ actually say?

Over about six weeks on tesofensine, the creator reported losing roughly 15 pounds in three weeks of aggressive dieting, then an additional 1.5 pounds during a vacation where he ate freely. He described early side effects including dry mouth, elevated heart rate, and "a really dark couple of days" of low mood, which he said resolved on their own. He also described a dramatically reduced appetite, saying he could think he wanted a donut, walk away, and genuinely not want it the next day.

To be clear: he is not claiming tesofensine cured anything or prescribing a dose. He is sharing a personal experience. That matters for how we evaluate this, but personal experience is not clinical evidence, and some of what he described deserves a closer look.

Does the science back this up?

Tesofensine's appetite suppression effects are real and documented, but the cardiovascular and mood side effects he described are also well-documented in trials and not something to wave off as personal quirks.

Tesofensine is a triple monoamine reuptake inhibitor, blocking reuptake of dopamine, serotonin, and norepinephrine. The landmark phase 2 trial (Astrup et al., 2008, The Lancet) showed subjects in the 0.5 mg group lost about 12.8 kg over 24 weeks compared to 2.2 kg on placebo. That is significant weight loss, and appetite suppression was the primary driver. So losing 15 pounds in three weeks of aggressive calorie restriction while on tesofensine is biologically plausible, though some of that is water weight and glycogen depletion, not purely fat.

The mood effects he described, including those "dark couple of days," are harder to dismiss. Given that tesofensine affects serotonin and dopamine pathways, psychiatric effects are a genuine concern. The same Lancet trial flagged increases in heart rate and blood pressure as the primary safety signals. Elevated heart rate is not a benign quirk. It was one of the main reasons tesofensine's development was slowed.

What did they get wrong (or right)?

He got the appetite suppression experience right in the sense that it tracks with what trials show. The mechanism is real. Where he stumbles is in framing the mood and heart rate side effects as things that just went away and therefore were not a big deal. That reasoning is not sound.

Saying "I knew that it was likely that I was just feeling" off because he was feeling off is circular logic. Mood disruption and elevated heart rate on a drug that directly manipulates dopamine, serotonin, and norepinephrine are pharmacological effects, not coincidences. Dismissing them because they resolved is like saying a fever was not drug-related because it broke. The Astrup 2008 trial documented heart rate increases of up to 7.4 beats per minute in the 0.5 mg group. That is not trivial.

He also deserves credit for something: the way he described his vacation eating, waiting to genuinely want food before eating it, actually reflects what appetite normalization is supposed to look like. That is not a crazy observation. It aligns with how reduced hedonic eating has been described in GLP-1 and monoamine-based appetite suppression research.

What should you actually know?

Tesofensine is not FDA-approved. It is not a GLP-1 receptor agonist, though it is often discussed in the same weight-loss drug conversations. It works through a completely different mechanism. As of publication, it has not completed phase 3 trials in the United States, meaning long-term safety data does not exist in the way it does for approved medications.

The side effects the creator described, including dry mouth, elevated heart rate, and mood changes, are consistent with what clinical trials have documented. These are not rare or unexpected. Anyone using this compound should be doing so under medical supervision with regular monitoring of cardiovascular metrics.

• Tesofensine is a research-stage compound, not an approved drug in most jurisdictions.
• Heart rate and blood pressure elevation are the primary documented safety concerns, not secondary ones.
• Mood changes on a drug affecting dopamine and serotonin pathways should be reported to a prescriber, not waited out alone.
• Rapid early weight loss of 15 pounds in three weeks on a severe calorie deficit includes a significant water and glycogen component, not purely fat.